Top Tweets for #KEYNOTE158
Based on results from #KEYNOTE158, the @FDA has approved #pembrolizumab and #pembrolizumab plus berahyaluronidase alfa for previously untreated patients with TMB-high unresectable or metastatic solid tumors.
Learn more: https://t.co/f6mGyPk7F8
8/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
Pivotal trials leading to FDA approval in 2L met MSI-H/dMMR #EndometrialCarcinoma
🔸Pembro: #KEYNOTE158 (phase 2)
🔹Dostarlimab: #GARNET (phase 1)
🔑Efficacy & safety data 📷👇
8/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
Pivotal trials leading to FDA approval in 2L met MSI-H/dMMR #EndometrialCarcinoma
🔸Pembro: #KEYNOTE158 (phase 2)
🔹Dostarlimab: #GARNET (phase 1)
🔑Efficacy & safety data 📷👇
#Pembrolizumab maintained or improved #HRQoL in patients with previously treated advanced MSI-H/dMMR #endometrialcancer #KEYNOTE158 @SGO_org @gyncsm @IGCSociety @ESGO_society @OSUWexMed @OncoAlert @myESMO @ASCO https://t.co/SxMcYvL2as
#Pembrolizumab monotherapy associated with #durable #response in subset of patients with #vulvar #SCC #KEYNOTE158 @SGO_org @OncoAlert @Gyne_Oncology @IGCSociety @ESGO_society @ASCO @acog @AmericanCancer @myESMO https://t.co/TTBzGnSZFI
Approval was based on #KEYNOTE158, Cohort D/K showing ORR 44-53% (based on line of therapy), median: 46%, mDOR: NR as shown in @JCO_ASCO @ASCO pub by O'Malley et al. https://t.co/WTa5dYEovI, making #biomarkers IMP for #endometrial cancers!
The OncoAlert🚨podcast🎙️Is NOW OUT discussing
OS TIVO3:Tivozanib Vs Sorafenib
@montypal
https://t.co/orRa0gNHMw
#KEYNOTE158 Pembrolizumab& TMB
Discussants @VivekSubbiah & @PatelOncology
https://t.co/9ZxLKEaVR5
Apple🍏
https://t.co/Hf90BAasql
Spotify
https://t.co/xaz1ccGdqa
@mgfakih analysis of the numbers
insight re future:
"Maybe this is an opportunity to start thinking about what we can do post-approval to better refine the treatment of those patients who are not included in these 10 disease types that were evaluated on #KEYNOTE158. "
#CRCSM
Fakih Fleshes Out Perceptions on Pembrolizumab Approval in TMB-High Solid Tumors @mgfakih @cityofhope #FDA https://t.co/AENyqODiMR
FDA Approves Pembrolizumab for TMB-High Solid Tumors #NeuroendocrineCancer included in #KEYNOTE158 https://t.co/OhxLk9buTs via @targetedonc
More on spectrum of #cancers in #Keynote158 & the tale of crossing curves similar to most #Immunotherapy studies. ✅tail of prolonged benefit noted in a subset of patients. As noted ☝🏽🧵 concern is “agnostic” approval is missing:
❌breast
❌colorectal
❌NSCLC
❌Prostate
@GerkIvan
The open-label #KEYNOTE158 trial accrued patients with:
anal
biliary
cervical
endometrial
salivary
thyroid
Vulvar
mesothelioma
Neuroendocrine
Small cell lung cancer
dMMR and MSIh
To receive pembrolizumab single agent: a ph2 basket trial.
Primary outcome measure: ORR
#kanser #onkolog #onkoloji #pembrolizumab #immünoterapi #FDA #rahimağzıkanseri #KEYNOTE158 #HPV https://t.co/jOpimVEZrd https://t.co/3EnrXTAbEV
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers